Related Experiment Videos
[Multidrug resistance: diagnostic approaches and difficulties]
Orsolya Rideg1, Péter Csutora, Tamás Magyarlaki
1Pécsi Tudományegyetem, Altalános Orvostudományi Kar, Laboratóriumi Medicina Intézet, Pécs.
Orvosi Hetilap
|June 11, 2005
Summary
Multidrug resistance (MDR) in cancer and transplant patients poses a significant challenge. Investigating MDR through genotyping and protein expression can help predict drug resistance, though diagnostic consensus is lacking.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Multidrug resistance (MDR) was recognized in the 1960s as simultaneous resistance of tumor cells to various chemotherapeutics.
- Transmembrane proteins are key mediators of MDR, with biochemical mechanisms extensively studied.
- MDR is a critical issue in treating hematological and solid organ tumors, and in immunosuppressive therapy for transplant recipients.
Purpose of the Study:
- To review current methods for investigating multidrug resistance (MDR).
- To highlight the importance of MDR in various medical fields.
Main Methods:
- Analysis of MDR genotyping and expression levels.
- Measurement of P-glycoprotein expression on cell surfaces.
- Assessment of outward transport of test molecules from cells.
Main Results:
- MDR genotyping and expression levels can predict drug resistance with reasonable accuracy.
- P-glycoprotein levels and molecule transport provide additional insights into MDR.
- Current testing methods aid in predicting or confirming MDR.
Conclusions:
- Despite advancements, uncertainties remain regarding MDR.
- Predictive testing for MDR shows promise but lacks standardized laboratory diagnostic consensus.